Skip to content

Author

Anurag Marasini

We have 6 of 10 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Nov 2026

Abstract 14482: Comparative Cardiovascular Outcomes of GLP-1 Receptor Agonists versus DPP-4 Inhibitors in Patients with Type 2 Diabetes: A Propensity Score-Matched Real-World Analysis

Background: Glucagon-like peptide-1 receptor agonists (GLP1RA) and dipeptidyl peptidase-4 inhibitors (DPP4i) are commonly used second-line agents in type 2 diabetes mellitus (T2DM). This large-scale real-world analysis compared their effects on major clinical outcomes. Methods: Using the TriNetX Research netwo...

Sajjad Ahmed Khan, Anurag Marasini · 0 citations
Nov 2026

Abstract 14492: Comparative Cardiovascular Outcomes of SGLT2 Inhibitors versus DPP-4 Inhibitors in Patients with Type 2 Diabetes: A Propensity Score-Matched Real-World Analysis

Background: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and dipeptidyl peptidase-4 inhibitors (DPP4i) are commonly used second-line agents in type 2 diabetes mellitus (T2DM). This large-scale real-world analysis compared their effects on major cardiovascular, renal, and diabetes-related complications. Me...

Sajjad Ahmed Khan, Anurag Marasini · 0 citations
Nov 2026

Abstract 14486: Comparative Cardiovascular and Mortality Outcomes of GLP-1 Receptor Agonists versus SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus: A Propensity Score-Matched Cohort Study

GLP-1 RA therapy was associated with significantly lower risks of major adverse cardiovascular outcomes and all-cause mortality compared with SGLT2 inhibitors, suggesting a potential advantage of GLP-1 RA therapy for long-term cardiovascular risk reduction in patients with T2DM.

Sajjad Ahmed Khan, Anurag Marasini · 0 citations
Open access Sep 2026

Clinical spectrum and burden of extrahepatic manifestations in chronic hepatitis B

Chronic hepatitis B virus (HBV) infection is associated with both hepatic and extrahepatic complications. While liver-related outcomes are well characterized, the burden, demographic patterns, and survival associated with extrahepatic manifestations (EHMs) remain incompletely defined. This study aimed to evaluate the s...

S. Khan, Anuj Subedi, Anurag Marasini et al. · 1 citation
Open access Sep 2026

Clinical outcomes associated with GLP-1 receptor agonist use in metabolic dysfunction–associated steatohepatitis

Metabolic dysfunction–associated steatohepatitis (MASH) is an important progressive liver disorder that can lead to hepatic decompensation, hepatocellular carcinoma (HCC), and premature death. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have demonstrated beneficial effects on metabolic dysfunction and liver h...

S. Khan, Anuj Subedi, Anurag Marasini et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.